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Abstract 
The cancer stem cell (CSC) hypothesis was first proposed over 40 years ago. Advances in 
CSC isolation were first achieved in hematological malignancies, with the first CSC demon-
strated in acute myeloid leukemia. However, using similar strategies and technologies, and 
taking advantage of available surface markers, CSCs have been more recently demonstrated in 
a growing range of epithelial and other solid organ malignancies, suggesting that the majority 
of malignancies are dependent on such a compartment.  
Primary liver cancer consists predominantly of hepatocellular carcinoma (HCC) and intra-
hepatic cholangiocarcinoma (ICC). It is believed that hepatic progenitor cells (HPCs) could be 
the origin of some HCCs and ICCs. Furthermore, stem cell activators such as Wnt/-catenin, 
TGF-, Notch and Hedgehog signaling pathways also expedite tumorigenesis, and these 
pathways could serve as molecular targets to assist in designing cancer prevention strategies. 
Recent studies indicate that additional factors such as EpCAM, Lin28 or miR-181 may also 
contribute to HCC progression by targeting HCC CSCs. Various therapeutic drugs that 
directly modulate CSCs have been examined in vivo and in vitro. However, CSCs clearly have a 
complex pathogenesis, with a considerable crosstalk and redundancy in signaling pathways, 
and hence targeting single molecules or pathways may have a limited benefit for treatment. 
Many of the key signaling molecules are shared by both CSCs and normal stem cells, which 
add further challenges for designing molecularly targeted strategies specific to CSCs but 
sparing normal stem cells to avoid side effects. In addition to the direct control of CSCs, many 
other factors that are needed for the maintenance of CSCs, such as angiogenesis, vasculo-
genesis, invasion and migration, hypoxia, immune evasion, multiple drug resistance, and ra-
dioresistance, should be taken into consideration when designing therapeutic strategies for 
HCC.  
Here we provide a brief review of molecular signaling in liver CSCs and present insights into 
new therapeutic strategies for targeting liver CSCs. 
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most 
common  cancer  worldwide  and  the  third  leading 
cause of cancer death [1]. Despite some progress in the 
treatment of cancers, existing therapies are limited in 
their ability to cure malignancies and to prevent me-
tastases and relapses. Surgery, radiofrequency abla-
tion  therapy  and  chemotherapy  are  all  directed  at 
reducing the bulk of the tumor  mass. However, on Int. J. Biol. Sci. 2011, 7 
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completion of therapy there is ultimately regrowth of 
tumor and relapse of diseases in the majority of cases 
[2-5]. Although the idea of tumor stem cells has been 
proposed for a number of decades, demonstration of 
their existence has only occurred within the last ten 
years. Recently, HCC progression has been thought to 
be  driven  by  cancer  stem  cells  (CSC)  through  their 
capacity for  self-renewal,  production  of heterogene-
ous progeny, resistance to chemotherapy and to lim-
itlessly  divide.  Advances  were  first  achieved  in  he-
matological malignancies, with the first CSC demon-
strated  in  acute  myeloid  leukemia.  However,  using 
similar  strategies  and  technologies,  and  taking  ad-
vantage of available surface markers, CSCs have been 
more  recently  demonstrated  in  a  growing  range  of 
epithelial  and  other  solid  organ  malignancies,  sug-
gesting  that  the  majority  of  malignancies  are  de-
pendent on such a compartment. Furthermore, many 
potentially and biologically significant surface mark-
ers  and  pathways  that  can  modulate  these 
stem/progenitor cells in cancer tissue have been suc-
cessfully identified based on their dual role both in 
embryogenic stem cell development and tumor acti-
vation or suppression. In this review, we demonstrate 
a brief and up-to date review of molecular signaling in 
liver CSC and present insights into new therapeutic 
strategies for liver CSCs. 
Liver stem cells in human liver regeneration 
The liver is both an exocrine and an endocrine 
gland, which performs complex functions and has the 
phenomenal ability to regenerate. This process ena-
bles the recovery of the lost mass without endanger-
ing the viability of the entire organism [6, 7]. Many 
studies suggest that the existence of two basic types of 
liver regeneration [8, 9]. After acute liver injury, he-
patic stem cells take part in normal tissue repair and 
homeostasis quickly [10]. In contrast, liver regenera-
tion after loss of hepatic tissue does not depend on 
these  kinds  of  cells,  but  on  the  proliferation  of  the 
existing mature hepatocytes, the parenchymal cells of 
the organ. In addition, other cells such as endothelial 
cells, Kuppfer cells, and Ito cells may also contribute 
to regeneration of the lost hepatic tissue [6].  
The  normal  liver  has  been  estimated  to  be  re-
placed by normal tissue approximately once a year or 
more [11]. Therefore replacement rate of the normal 
adult liver was calculated to be 0.005-0.0025% at any 
time  [12].  However,  this  slow  normal  renewal  rate 
differs from the rapid proliferate response to loss of 
hepatic mass. In rodents, when two-thirds of the liver 
is resected (partial hepatectomy) the remaining rem-
nant can regrow to the original liver size in approxi-
mately 10 days [7, 13]. In response to this stimulus, the 
normally quiescent hepatocytes leave G0 to enter the 
cell cycle under the influence of many growth factors. 
Hepatocyte proliferation begins in the periportal re-
gion of the liver and spreads to the centrilobular re-
gion.  This  regenerative  response  requires  each 
hepatocyte to undergo only 2 rounds of replication to 
restore normal liver size. Hepatocytes are capable of 
large-scale clonal expansion within a diseased liver. 
Following very extensive liver damage or in situations 
in  which  hepatocyte  regeneration  after  damage  is 
compromised, a potential stem cell component locat-
ed  within  the  smallest  branches  of  the  intrahepatic 
biliary  tree  is  activated.  Hepatic  progenitor  cells 
(HPCs) amplify a biliary population of transit ampli-
fying cells that are bipotential, capable of differenti-
ating into either hepatocytes or cholangiocytes. These 
cells have been observed after severe hepatocellular 
necrosis,  chronic  viral  hepatitis,  alcoholic  liver  dis-
ease, and nonalcoholic fatty liver disease. It is thought 
that the activation of a potential stem cell compart-
ment  leads  to  the  formation  of  reactive  ductules, 
anastomosing cords of immature biliary cells with an 
oval nucleus and small rim of cytoplasm. Differentia-
tion toward the hepatocyte lineage occurs via inter-
mediate hepatocytes, polygonal cells with a size and 
phenotype intermediate between progenitor cells and 
hepatocytes. Intermediate hepatocytes become more 
numerous with time and extend further into the liver 
lobules.  This  sequence  of  changes  suggests  gradual 
differentiation  of  human  progenitor  cells  into  inter-
mediate hepatocytes.  
The  Hepatocyte  proliferation  rate  increases  in 
chronic hepatitis with increased histological appear-
ance of cellular damages until cirrhosis is reached, at 
which point the proliferation rate falls [14]. This fall 
probably reflects replicative senescence, although the 
diversion  of  blood  flow  through  the  liver  probably 
plays a part [15]. The reduction in hepatocyte prolif-
eration  indices  in  chronic  hepatitis  occurs  concur-
rently with the activation of HPCs [16, 17]. The de-
velopment  of  an  oval  cell  reaction  in  response  to 
hepatocyte  replicative  senescence  has  been  demon-
strated in a transgenic mouse model of fatty liver and 
DNA  damage  [18].  In  this  model,  mice  developed 
fatty  livers  and  large  number  of  senescent  hepato-
cytes.  A  striking  oval  cell  response  related  to  the 
number  of  senescent  mature  hepatocytes.  The 
hepatocytes  generated  from  oval  cells  in  severe-
ly-damaged cirrhotic livers may have a high risk for 
neoplastic transformation. 
Stem cells in the liver are proposed to be from 
two origins: endogenous or intrahepatic and exoge-
nous  or  extrahepatic.  Included  in  the  intrahepatic 
stem  cell  compartment  are  the  HPCs  which  are Int. J. Biol. Sci. 2011, 7 
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greater  in  number  but  with  short-term  proliferative 
capacity. HPCs are thought to be localized within the 
canals of Hering, interlobular bile ducts [19, 20]. In-
cluded in the extrahepatic stem cell compartment are 
cells derived from bone marrow and peripheral blood 
cells; these cells are usually few but with long-term 
proliferation capacity [21-23]. 
Human Liver Progenitor Cells and Cancer 
Stem Cells 
Human hepatic stem cells most likely give rise to 
HCC as well as ICC [7, 24-26]. The hypothesis that 
HCC arises from HPCs is supported by the finding 
that  many  tumors  contain  an  admixture  of  mature 
cells  and  cells  phenotypically  similar  to  HPCs.  De-
tailed  immunophenotyping  of  HCCs  revealed  that 
28-50% of HCCs express markers of progenitor cells 
such as CK7 and CK19 [27]. These tumors also consist 
of cells that have an intermediate phenotype between 
progenitors and mature hepatocytes. In fact, patients 
who have HCCs that express hepatocyte and biliary 
cell markers such as albumin, CK7 and CK10 carry a 
significantly poorer prognosis and have a higher re-
currence rate after surgical resection and liver trans-
plantation [28]. Cells resembling HPCs have also been 
noted in hepatoblastoma; the most common liver tu-
mors in children which are widely believed to be stem 
cell  derived  given  there  can  be  both  epithelial  and 
mesenchymal  tissue  components.  These  tumors  can 
even  have  structures  mimicking  intrahepatic  bile 
ducts and form ductal plate-like structures [29] (Fig. 
1). 
 
 
Figure 1. Implication of Stem Cells in Liver Development and Hepatic Tumorigenesis. Normal hepatic stem cells are 
characterized by their ability to self-renew and differentiate, which leads to formation of a normal liver tissues. Oncogenic 
mutations in normal stem/progenitor cells or even in differentiated cells enhance or endow the cells with self-renewal 
capability. Consequently, these cells function as cancer stem cells and contribute to the formation of bulk tumors. 
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Liver cancer stem cell and primary liver can-
cer 
Hepatocellular carcinoma 
The  CSC  hypothesis  is  based  on  the  idea  that 
stem cells are present also in cancer tissue and a hier-
archy of cells is formed, as is the case with normal 
tissue. Tumor formation, growth, and propagation are 
maintained by a minute proportion of cells with stem 
cell-like properties. Now, CSCs in HCC can be identi-
fied by several cell surface antigens including c-kit, 
CD133, CD90, CD44, OV6, and CD326 (EpCAM), or 
by selecting the side population (SP) cells by Hoechest 
dye-staining. 
SP cells in HCC cells possess high proliferation 
potential, tumorigenicity, and anti-apoptotic proper-
ties  compared  with  those  of  non-SP  cells  [30,  31]. 
Furthermore,  CD133+  cells  isolated  from  HCC  cells 
possess a greater ability to form tumors in vivo and 
have characteristics similar to those of progenitor cells 
including  the  expression  of  “stemness”  genes,  the 
ability  to  self-renew,  and  the  ability  to  differentiate 
into  nonhepatocyte-like  lineages  [32].  In  addition, 
CD133+ HCC cells represented only a minority of the 
tumor cell population in human HCC specimens, and 
increased  CD133  expression  levels  were  correlated 
with increased tumor grade, advanced disease stage, 
shorter overall survival, and higher recurrence rates 
compared with patients with low CD133 expression 
[33] . Tumor associated calcium signal transducer 1 
(TACSTD1), which encodes a pancarcinoma antigen 
epithelial  cell  adhesion  molecule  (EpCAM),  was 
identified to be an early biomarker of HCC [34, 35]. 
EpCAM  is  a  direct  transcriptional  target  of  the 
Wnt--catenin  canonical  signaling  pathway.  Ep-
CAM+alpha-fetoprotein  (AFP)+  HCC  subtype  had 
features  of  hepatic  stem/progenitor  cells,  and  Ep-
CAM+  HCC  cells  were  correlated  with  tumor  pro-
gression and invasiveness. Additionally, this surface 
molecule  is  also  highly  expressed  in  premalignant 
hepatic tissues, HPCs and bile duct epithelium, but 
not in most adult hepatocytes [35-37].  
Intrahepatic Cholangiocarcinoma 
The  origin  of  intrahepatic  cholangiocarcinoma 
(ICC)  is  much  less  defined  when  compared  with 
HCC. However, since that incidence and mortality of 
ICCs  clarifying  the  origin  of  these  tumors  is  im-
portant. Recent studies suggest that some ICCs could 
arise from liver stem cells rather than from  mature 
cholangiocytes [38]. This concept is supported by the 
identification of a combined hepatocellular cholangi-
ocarcinoma  (CHC),  which  have  morphological  and 
phenotypical intermediate features between HCC and 
ICC [39]. The ability of HPCs to differentiate towards 
the biliary and the hepatocytic lineages gave rise to 
the hypothesis that transformed HPCs are the source 
of  origin  of  intermediate  primary  liver  carcinomas. 
Some  animal  models  reveal  that  ICC  can  originate 
from HPCs [40, 41]. Furthermore, in a few cases of 
human ICCs, it has been reported that some tumor 
cells express specific markers of liver stem cells, indi-
cating a possible stem cell origin [42, 43]. However, 
there is currently not enough data to make a state-
ment regarding a stem cell origin of ICC and further 
immunohistochemical  characteristics  related  to  the 
expression  of  hepatic  stem  cell  markers  in  ICCs 
should be elucidated. 
Molecular signaling of Liver Cancer Stem 
Cells 
Wnt/-catenin signaling pathway 
The Wnt/-catenin pathway is an evolutionarily 
well-conserved  pathway  to  be  essential  to  normal 
cellular processes such as development, growth, sur-
vival, regeneration, and self-renewal [44]. Disruption 
of Wnt/-catenin signaling results from both genetic 
and epigenetic changes is associated with a range of 
diseases  and  is  frequently  found  in  many  cancers, 
especially  colon  cancer  and  HCC.  Disrupted 
Wnt/-catenin  signaling  by  mutational  and 
non-mutational events is observed in about one third 
of all HCCs which emphasizes the importance of this 
pathway  in  hepatocarcinogenesis  [45,  46].  The  Wnt 
pathway diversifies into two main branches, i.e., ca-
nonical  (-catenin-dependent)  and  non-canonical 
(-catenin-independent),  which  play  critical  roles  in 
specifying cellular fates and movements, respectively, 
during both embriogenic development and adult tis-
sue regeneration [47-49].  
Wnt  ligands  signal  through  binding  to  seven 
transmembrane  Frizzled  (Fzd)  receptors  and  single 
transmembrane  lipoprotein  receptor-related  protein 
(LRP)  5  or  6  co-receptors  [50].  Canonical  signaling 
mediated by ligands such as Wnt3a inhibits a multi-
protein degradation complex consisting minimally of 
axin, adenomatous polyposis coli (APC) and glycogen 
synthase  kinase  3  (GSK3)  [51-54].  This  inhibition 
culminates in nuclear translocation of -catenin, ena-
bling it to interact with T-cell factor (TCF)/lymphoid 
enhancer factor (LEF) transcription factors to regulate 
gene expression [55].  
Non-canonical signaling, which is much less de-
fined, is mediated by ligands such as Wnt11 that uses 
the  same  Fzd  receptors  [56].  The  Wnt-Fzd  complex 
interacts with heterotrimeric G and Dv1 proteins to 
activate  phospholipase  C,  which  then  generates  di-Int. J. Biol. Sci. 2011, 7 
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acylglycerol and inositol-phosphatase from phospha-
tidyl inositol 4, 5-biphosphate and increase intracel-
lular calcium concentration. The Wnt-Fzd-G protein 
complex  can  also  stimulate  p38  kinase  and  activate 
phosphodiesterase  6,  which  hydrolyzes  cyclic  GMP 
and results in the inactivation of protein kinase G and 
an  increase  in  intracellular  calcium.  Wnt-mediated 
increase in intracellular Ca2+ activates protein kinase 
C  and  calmodulin-dependent  kinase  2  (CamKⅡ). 
CamKⅡ can activate calcineurin (CAN), and subse-
quently  the  NF-AT  family  of  calcineurin-dependent 
transcription factors, as well as TAK1-NLK kinases. 
Signaling  through  the  TAK-NLK  kinases  are  pro-
posed to inhibit canonical Wnt signaling. This path-
way stimulates  the Jun  NH2-terminal kinase (JNK), 
Ca2+/CaMKⅡ  and  PKC  pathways.  Both  pathways 
interact  with  each  other,  and  in  some  cases, 
non-canonical  signaling  antagonizes  the  canonical 
pathway [57]. 
The Wnt receptor, FZD-7 is found to be overex-
pressed in up to 90% of HCCs [45, 58]. Twenty to 40% 
of HCCs bear abnormal cytoplasmic and nuclear ac-
cumulation  of  -catenin  [59,  60].  However,  not  all 
studies show a correlation between elevated nuclear 
-catenin and expression of its transcriptional targets 
implying that the expression of these target genes is 
likely to be regulated by alternative signaling mecha-
nisms [59, 60]. While most of the proceeding muta-
tions have not been detected in allelotype analysis, it 
is salient to  note that deletions in the AXIN1 locus 
(16p)  have  been  described  in  HCC.  Axin1  and 
-catenin mutations have also been identified in ap-
proximately  25%  of  HCCs  [45,  46,  61-64]  ,  while 
overexpression  of  the  FZD-7  receptor  and  glycogen 
synthase kinase-3 (GSK-3) inactivation can also lead 
to  aberrant  -catenin  pathway  activation.  Elevated 
expression of Wnt and its downstream mediators was 
also reported in EpCAM+ liver CSCs [35]. It has been 
demonstrated  that  murine  hepatic  stem/progenitor 
cells transduced with mutant -catenin acquired ex-
cessive self-renewal capability and tumorigenicity in a 
similar  fashion  to  BMI1.  In  addition,  the 
Wnt/-catenin  pathway  is  activated  in  both  rodent 
oval cells and OV6-positive tumor cells, and it leads to 
HCC  chemoresistance  [65].  These  findings  indicate 
that Wnt/-catenin signaling plays an important role 
in the maintainance of CSCs.  
Recently, the mechanisms leading to malignant 
transformation  of  stem/progenitor  cells  were  effec-
tively  addressed  in  pediatric  tumors  [66].  Hepato-
blastoma is a malignant embryonal tumor of the liver, 
which  differs  from  HCC  by  distinct  morphological 
patterns  reminiscent  of  hepatoblasts,  the  bipotent 
precursors of hepatocytes and cholangiocytes, and of 
their arrangement in the developing liver. Integrated 
molecular and genetic studies of hepatoblastoma dis-
closed two major molecular subclasses of tumors that 
relate early and late phases of prenatal liver devel-
opment.  It  has  been  suggested  that  hepatoblastoma 
might arise from impairment of the normal liver dif-
ferentiation  program  associated  with  excessive 
Wnt/-catenin signaling [62]. In addition, the inter-
play of Wnt/-catenin and Myc signaling in imma-
ture  tumors  activates  a  distinct  transcriptional  pro-
gram that correlates with tumor aggressiveness. Cor-
relation between stage of hepatic differentiation and 
clinical  manifestation,  notably  vascular  invasion, 
metastatic spread, and patient survival, was also es-
tablished [66]. These finding highlight the important 
role of dysregulated Wnt/-catenin signaling in the 
transformation of stem/progenitor cells. 
Recently,  EpCAM  was  identified  as  a  direct 
transcriptional  target  of  Wnt/-catenin  signaling  in 
HCC [35]. Adult hepatocytes are EpCAM-, while the 
bile duct epithelium is EpCAM+. In addition, expres-
sion of EpCAM was observed during fetal liver de-
velopment, liver regeneration, and liver repair asso-
ciated with cirrhosis. Moreover, EpCAM is a marker 
of  hepatic  progenitors,  suggesting  that  EpCAM+ 
HCCs are of hepatic progenitor cell origin [67].  
The EpCAM signaling can be activated by regu-
lated intramembrane proteolysis (RIP) and shedding 
of  extracellular  domain  of  EpCAM  (EpEX)  [68].  Se-
quencial cleavage of EpCAM by tumor-necrosis-factor 
alpha  converting  enzyme  (TACE/ADAM17)  and  a 
gamma-secretase  complex  containing  presenilin  2 
(PS-2) result in release of EpEX into the culture me-
dium, and release of an intracellular domain of Ep-
CAM (EpICD) into the cytoplasm. EpICD becomes a 
part of a large nuclear complex containing transcrip-
tional regulators -catenin and Lef, both of which are 
components  of  Wnt/-catenin  signaling.  Four  and 
one-half LIM domain protein 2 (FHL2) is essential for 
signal transduction by EpCAM. FHL2 further regu-
lates  localization  and  activity  of  TACE  and  PS-2. 
Through  its  function  as  a  co-activator  of  -catenin, 
FHL2 links EpICD with specific DNA sequences and 
gene regulation. FHL2 has the potential to serve as a 
scaffolding  protein  for  various  signaling  proteins 
used by EpCAM [69]. A number of EpCAM-regulated 
target genes have been identified including c-myc and 
cyclins, and additional genes involved in cell growth 
and proliferation, cell cycle, and cell death. Upon in-
terference with E-cadherin, EpCAM may increase the 
availability of its interaction partner -catenin in the 
soluble fraction. Cross-talk with the Wnt pathway is 
possible at the level of -catenin and Lef-1 interactions Int. J. Biol. Sci. 2011, 7 
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with EpICD, and known for induction of the EPCAM 
promoter by Tcf4. These findings indicated that ex-
pression of EpCAM strongly linked with proliferation 
of stem cells and cancer development by cancer initi-
ating cells after aberrant EpCAM re-expression. 
TGF- family 
The TGF- signaling pathway appears to be most 
prominent at the interface between development and 
cancer in liver and gut epithelial cells [70]. Smad sig-
naling has been shown to be pivotal for embryogenic 
hepatocyte proliferation, as well as in the formation of 
gastrointestinal  cancers  [71,  72].  Smad  activation  is 
modulated by various receptor- or Smad-interacting 
proteins  that  include  ubiquitin  and  small  ubiqui-
tin-related modifier (SUMO) ligases, as well as multi-
ple  adaptor  proteins  that  include  Smad  anchor  for 
receptor  activation  (SARA),  Filamin  and 
2-SPECTRIN. 2-SPECTRIN is crucial for the prop-
agation  of  TGF-  signaling.  Specifically, 
2-SPECTRIN associates with Smad3, presenting it to 
the cytoplasmic domain of the TGF- Type I receptor 
complex;  followed  by  heteromeric  complex  associa-
tion  with  Smad4,  nuclear  translocation  and  target 
gene activation  [73]. Disruption of 2-SPECTRIN in 
mice leads to disruption of TGF- signaling and re-
sults  in  a  phenotype  similar  to  Smad2+/-/Smad3+/- 
mutant mice, mid-gestational death due to gastroin-
testinal,  liver,  neural  and  heart  defects,  and  loss  of 
intrahepatic bile ducts. Interestingly, while the liver 
lineage is established, hepatocytes are poorly formed 
and liver architecture is lost with an absence of prim-
itive bile ducts as in the Smad2+/-/Smad3+/- mutants. 
Moreover, bile duct formation can be induced in liver 
explants cultures treated with TGF- [74]. 
 Many  studies  have  reported  a  reduction  of 
TGF- receptors in up to 70% of HCC [58, 75]. How-
ever, Smad proteins shown to be impaired in other 
cancers appear to play a minor role in HCC [76, 77]. 
Yet, TGF- levels in serum and urine are increased in 
HCC patients [78, 79]. In addition, up to 40% of HCC 
have increased TGF- expression based on immuno-
histochemical  analysis  [80,  81].  High  TGF-  levels 
have been correlated with advanced clinical stage of 
HCC  [82,  83].  This  dual  role  of  TGF-  signaling  in 
HCC was explained by its effect on the tumor tissue 
microenvironment  and  on  selective  loss  of  the 
TGF--induced antiproliferative pathway [75]. Tumor 
cells that have selectively lost their growth-inhibitory 
responsiveness  to  TGF-  but  retain  an  otherwise 
functional TGF- signaling pathway may exhibit en-
hanced migration and invasive behavior in response 
to TGF- stimulation. TGF- signaling also has been 
shown to induce an epithelial to mesenchymal transi-
tion (EMT) process in tumor cells. EMT leads to en-
hanced migration and invasiveness [84]. Recently, loss 
of ELF, a TGF- adaptor and signaling molecule, in 
the  liver  leads  to  cancer  formation  by  deregulated 
hepatocyte  proliferation  and  stimulation  of  angio-
genesis  [85].  More  recently,  it  was  reported  that 
STAT3/Oct4-positive  HCC  cells,  which  have  dys-
functional TGF- signaling, are likely cancer progen-
itor cells that have the potential to give rise to HCC 
[86].  
Notch pathway 
The  Notch  signaling  pathway  plays  an  im-
portant role in stem cell self-renewal and differentia-
tion [87-90]. However, other signaling pathways in-
fluence  whether  Notch  functions  as  a  tumor  sup-
pressor or oncogene in a particular tissue [91]. Notch 
signaling is activated through four receptors (Notch 
1-4) that can interact in a redundant manner with five 
ligands  of  the  Delta/Jagged  family  [49,  92].  Ligand 
binding  triggers  a  -sevretase-dependent  proteolytic 
cleavage of Notch receptor and the release of Notch 
intracellular  domain  (NCID)  to  the  nucleus  [93]  , 
which  in  turn  displaces  the  co-receptors  associated 
with CSL transcription factors (CBF1 in humans; RBPJ 
in mice). Activating transcription factors are then re-
cruited and expression of target genes such as Hairy 
and Enhancer of Split (HES1 and HES5) and Deltex1 is 
induced [92, 94]. 
Notch signaling plays a well-defined role in liver 
embryogenesis and bile duct formation. In addition, 
Notch family members are involved in angiogenesis 
and endothelial sprouting [95-97]. Increased expres-
sion  of  genes  involved  in  this  pathway  has  been 
shown  in  CD133+  liver  cancer  cells  as  compared  to 
CD133-. The activated intracellular form of Notch3, as 
well as the notch ligand Jagged, is highly expressed in 
HCC  [98-100].  Notch-dependent  transformation  is 
associated with extracellular signal-regulated kinase 
activation  downstream  of  the  Ras  pathway,  which 
increases Notch mRNA stability and is required for 
transcription  of  the  Notch  target  gene,  Hes-1  [101, 
102]. Conversely, Notch-1 has been reported to func-
tion  as  a  tumor  suppressor  and  participate  in 
cross-talk  with  other  signaling  pathways  such  as 
Ras/Raf/MEK/ERK  through  the  regulation  of  the 
PTEN tumor suppressor [103]. Recent evidence indi-
cates that activation of Notch1 signaling increases the 
expression level of death receptor 5 (DR5) with en-
hancement of TRAIL-induced apoptosis in vitro and in 
vivo [104, 105]. Inhibitors of the NOTCH pathway are 
currently  under  investigation  in  clinical  trials  for 
treating  solid  tumors  although  the  effectiveness  of Int. J. Biol. Sci. 2011, 7 
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NOTCH  pathway  inhibitors  in  treating  liver  cancer 
remains unclear. 
Hedgehog signaling 
Conserved  from  Drosophilia  to  humans,  the 
Hedgehog  (HH)  pathway  has  a  central  role  in  em-
bryonic development and adult tissue homeostasis by 
controlling  cell  fate  specification  and  pattern  for-
mation  [49,  106].  The  functional  importance  of  this 
pathway  is  illustrated  by  the  multiple  birth  defects 
and malignancies associated with mutations and/or 
aberrant activation of the pathway [107, 108]. Three 
HH  ligands  Sonic  (SHH),  Indian  (IHH)  and  Desert 
(DHH)  have  been  identified  in  mammals  that  can 
bind  interchangeably  to  two  related  twelve-pass 
membrane Patched (Ptc) receptors [109] . In the ab-
sence of ligand, Ptc antagonizes the pathway by pre-
venting the activity of another transmembrane pro-
tein  Smoothened  (Smo)  [110,  111].  Binding  of  HH 
ligands  to  Ptc  relieves  this  inhibition  and  activates 
target  gene  transcription  factors  (Gli-1,  Gli-2,  Gli-3) 
[112, 113]. Like -catenin, after ligand stimulation, Gli 
accumulates in the nucleus and induces transcription 
of  genes  related  to  cell  cycle  and  growth  including 
insulin-like  growth  factor-2  (IGF-2),  cyclins,  and 
-catenin. The different Gli proteins exhibit activating 
or repressing transcriptional activators depending on 
proteolytic processing of the full-length proteins. Gli-1 
and  Gli-2  mainly  act  as  transcriptional  activators, 
while Gli-3 generates a repressor form (Gli3R) in the 
absence or inhibition of HH signaling [109, 114, 115]. 
Although  functional  significance  of  Gli-3  has  been 
demonstrated by genetic inactivation [116] , the mo-
lecular mechanisms that control Gli-3 interactions and 
targets are largely undefined, whereas the dynamic 
interplay  between  Gli-1  and  Gli-2  signaling  is  well 
documented.  
Sonic is the predominant isoform in the liver. Up 
to 60% of human HCC express Sonic, and concomi-
tant  downregulation  of  Gli-related  target  genes  are 
found  after  specific  blockade  of  this  pathway  [117, 
118]. Furthermore, tumorigenic activation of Smo can 
mediate  overexpression  of  c-myc,  a  gene  known  to 
play  an  important  pathogenic  role  in  liver  carcino-
genesis [118]. Moreover, recent studies also showed 
that activation of Hedgehog signaling is critically re-
lated  to  CSCs  and  EMT  features  in  many  types  of 
cancers including colon, gastric, esophagus, hepatic, 
and other cancers.  
BMI1 signaling pathway 
BMI1  is  a  part  of  the  polycomb  group  genes 
(PcG) that are highly conserved throughout evolution. 
BMI acts as an epigenetic chromatin modifier and is 
known for its contribution to embryonic and stem cell 
self-renewal programs [119]. It is frequently overex-
pressed  in  different  cancer  types  and  disruption  of 
BMI1 signaling has been linked to the activation of the 
hedgehog pathway in some cancers, such as medul-
loblastoma  [120, 121]. Furthermore, BMI1 upregula-
tion is associated with malignant transformation and 
acquisition of the malignant phenotype in HCC [122]. 
Aberrant BMI1 expression is reported in many CSC 
populations and it has been shown to have a critical 
role in maintaining and propagating the SP popula-
tion in liver cancer. BMI1 is also highly expressed in 
CD133+  liver  CSCs.  The  role  of  BMI1  in  liver  CSC 
maintenance  is  confirmed  by  ectopic  expression  of 
BMI1  in  murine  hepatic  stem/progenitor  cells.  In 
these  cells,  BMI1  and  the  Wnt/-catenin  pathway 
regulate  the  self-renewal  of  normal  or  cancer  stem 
cells  in  liver.  Furthermore,  BMI1  knockdown  in  SP 
cells  completely  abolished  the  tumorigenicity  of  SP 
cells [32, 123, 124]. Moreover, repression of targets of 
BMI1 plays a crucial role in the oncogenic transfor-
mation of hepatic stem/progenitor cells [125]. 
In addition to these signaling pathways, signal 
transducer and activator of transcription 3 (STAT3), 
mainly activated by IL-6 and its related cytokine, and 
IL-22 has been shown to play key roles in acute phase 
response,  a  protection  against  liver  injury,  the  pro-
motion of liver regeneration [126]. Furthermore, hy-
peractive STAT3 signaling results in expansion of oval 
cell numbers and trigger wound healing, cell migra-
tion,  and  proliferation  [127,  128].  This  signaling 
pathway may take part an important role of mainte-
nance of CSCs. 
Stem cell signaling network 
Multiple  studies  have  suggested  that 
Wnt/-catenin,  Notch,  Hedgehog,  FGF,  and 
TGF-/BMP  signaling  network  is  implicated  in  the 
maintenance  of  tissue  homeostasis  by  regulating 
self-renewal of normal stem cells as well as prolifera-
tion  or  differentiation  of  progenitor  cells  [129-133]. 
Especially, it is well established that Wnt/-catenin 
and  Hedgehog  signaling  pathways  are  critical  for 
embryogenic development, as well as in the biology of 
CSCs and in the acquisition of EMT. Breakage of the 
signaling network for normal stem cells leads to the 
transformation  to  CSC.  Alternatively,  acquisition  of 
self-renewal potential in progenitor cells due to epi-
genetic change or genetic alteration of stem cell sig-
naling related genes gives rise to CSC. Detailed anal-
yses on the dysregulation of Wnt/-catenin, Notch, 
Hedgehog, FGF, and TGF-/BMP signaling pathways 
in CSCs derived from a various type of human tissues 
or  organ  should  be  systematically  investigated  to Int. J. Biol. Sci. 2011, 7 
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better understand CSCs themselves as well as the role 
they play in carcinogenesis. 
miRNA 
MiRNAs  play  critical  roles  in  many  biological 
processes  including  cancer  by  directly  interacting 
with specific messenger RNAs (mRNAs) through base 
pairing and then inhibiting expression of the target 
genes  through  a  variety  of  molecular  mechanisms. 
MiRNAs  can  undergo  aberrant  regulation  during 
carcinogenesis, and they can act as oncogenes or tu-
mor suppressor genes. Disruption of miRNA expres-
sion levels in tumor cells may result from distorted 
epigenetic  regulation  of  miRNA  expression,  abnor-
malities  in  miRNA  processing  genes  and  proteins, 
and the location of miRNAs at cancer-associated ge-
nomic regions.  Consequently, abnormal miRNA ex-
pression  is  a  ubiquitous  feature  of  solid  tumors  in-
cluding HCC [134]. In liver carcinogenesis, miRs have 
been found to have both tumor suppressive (miR-122, 
miR-26, miR-223) and oncogenic (miR-130b, miR-221, 
miR-222) activity [135-139]. Clearly, miRNAs play a 
critical  role  in  carcinogenesis  and  oncogenesis. 
Emerging  evidence  suggests  that  certain  abnormal 
miRNA  expression  induces  CSC  dysregulation,  re-
sulting in unlimited self-renewal and cancer progres-
sion. Therefore, miRNA expression is a vital key to 
CSC dysregulation. 
Lin28 and let-7 signaling 
Lin28  was  first  characterized  in  the  nematode 
Caenorhabditis  elegans  as  an  important  regulator  of 
developmental timing [140, 141]. Recently, Lin28 was 
used together with OCT4, NANOG and SOX2 to re-
program  human somatic fibroblasts to pluripotency 
[142].  Overexpression  of  these  stem  cell  factors  has 
been  reported  to  promote  oncogenesis  by  driving 
self-renewal and proliferation [142]. Moreover, poorly 
differentiated,  aggressive  human  tumors  have  re-
cently  been  shown  to  have  an  embryonic  stem 
cell-like  gene  expression  signature;  these  stem  cell 
factors have also been reported to have roles in tumor 
progression. 
LIN28 and LIN28B are overexpressed in primary 
human tumors and human cancer cell lines (overall 
frequency 15%)  [143]. The mammalian homologs of 
lin-28, Lin28 and Lin28b, bind to the terminal loop of 
the precursors of let-7 family miRNAs and block their 
processing into mature miRNAs [144, 145]. In HCC, 
LIN28B-expressing  tumors  are  associated  with  ad-
vanced stage [143]. Moreover, LIN28B-expression was 
associated with a significantly increased incidence of 
early  recurrence.  LIN28  is  associated  with  an  ad-
vanced  disease  and  poor  clinical  outcome  in  HCC 
[143, 146, 147]. The initiation of hepatocarcinogenesis 
is linked to chronic inflammation clinically and epi-
demiologically. The positive feedback loop involving 
NF-κB, Lin28B, let-7, and IL-6 is required for mainte-
nance  of  the  transformed  phenotype  and  stem  cell 
population [148] (Fig. 2). 
miR-181 
Mir-181  was  first  characterized  in  the  patients 
with acute myeloid leukemia as a predictor of prog-
nosis. Recently, we have identified a subset of highly 
EpCAM+ HCC  cells  from  AFP+  tumors  with  cancer 
stem/progenitor  cell  features  [149].  MiR-181  family 
members  are  up-regulated  in  EpCAM+AFP+  HCC 
cells. Moreover, miR-181 family members were highly 
expressed in embryogenic livers and isolated hepatic 
stem  cells.  Forced  expression  of  miR-181  induces 
stemness of  HCC cells  while inhibiting  miR-181 re-
sults in cell differentiation and inhibition of tumor-
igenicity.  In  addition,  we  identified  three  targets  of 
miR-181, caudal-related homeobox 2 (CDX2), GATA6 
and NLK. CDX2 and GATA6 are transcription factors 
and link to cancer stemness. NLK is a negative regu-
lator  of  Wnt/-catenin  signaling.  We  propose  that 
miR-181  maintains  HCC  stemness  by  inhibiting 
CDX2, GATA6 or NLK. MiR-181 could directly target 
hepatic  transcriptional  regulators  of  differentiation 
and  an  inhibitor  of  Wnt/-catenin  signaling  [149]. 
Therefore, miR-181 and its signaling molecules could 
be molecular targets for inhibiting CSCs (Fig. 3). 
Therapeutic target of Molecular signaling 
The successful eradication of cancer requires an-
ticancer therapy that affects the differentiated cancer 
cells and the potential CSC population [150, 151]. At 
present,  conventional  anticancer  therapies  include 
chemotherapy,  radiation  and  immunotherapy  kill 
rapidly  growing  differentiated  tumor  cells,  thus  re-
ducing tumor mass but potentially leave behind can-
cer-initiating cells. Therapies that exclusively address 
the pool of differentiated cancer cells but fail to erad-
icate the CSC compartment might ultimately result in 
relapse and the proliferation of therapy-resistant and 
more  aggressive  tumor  cells.  An  ideal  drug  regime 
would kill differentiated cancer cells and, at the same 
time, specifically, selectively and quickly target and 
kill CSCs to avoid toxic side effects for other cell types 
and to disrupt the self-protection potential of CSCs. 
Moreover, CSCs clearly have a complex pathogenesis, 
with the potential for considerable crosstalk and re-
dundancy in signaling pathways, and hence targeting 
single  molecules  or  pathways  may  have  a  limited 
benefit  in  treatment.  The  use  of  combinations  of 
therapies  may  be  needed  to  overcome  the  complex Int. J. Biol. Sci. 2011, 7 
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network of signaling pathways, and ultimately inhibit 
the signaling that controls tumor growth and survival. 
In addition to the factors in which CSCs possess by 
themselves,  microenvironment  surrounding  them  is 
important  for  maintenance,  such  as  angiogenesis, 
vasculogenesis, and hypoxia. Many new therapeutic 
strategies targeting CSCs at various stages of differ-
entiation and microenvironment of CSCs have been 
tried. We will be discussed below (Fig. 4).  
 
 
 
 
Figure 2. Let-7 and Lin28 in Development and Tumorigenesis. (Top) During normal development, the RNA-binding protein 
Lin28 is highly expressed in stem and progenitor cells. Lin28 blocks processing of let-7 miRNA precursor molecules into 
mature miRNAs, thereby maintains expression of genes that drive self-renewal and proliferation. As progenitor cells dif-
ferentiate, Lin28 expression decreases, which allows let-7 processing and increased production of mature let-7 miRNAs. 
Let-7 miRNAs repress the expression of genes involved in self-renewal resulting in lineage commitment and terminal dif-
ferentiation. (Bottom) Many molecules contribute to the balancing act of the Lin28/let-7 link in cellular differentiation and 
tumor progression. An imbalance between Lin28 and let-7 induced by these molecules can result in cellular transformation. 
 
 Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
526 
 
Figure 3. Potential Signalling Pathways of Wnt/β-Catenin, EpCAM and miR-181 Activated in Hepatic Cancer Stem Cells. 
Upon cleavage by TACE/PS-2, EpICD translocates into the nucleus in a multiprotein complex. Together with FHL2, 
β-catenin and Lef-1, EpICD contacts DNA at Lef-1 consensus sites. Owing to its ability to inhibit E-cadherin-mediated 
adhesion, EpCAM provides itself with β-catenin as a central interacting protein.  
 
 
 
Figure 4. Strategies in Eradicate Liver Cancer Stem Cells. CSCs are protected from conventional therapies by changing 
their microenvironment and self-protection. Specifically targeting any of these areas may lead to the eradication of the CSCs. 
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Blockage of CSC pathways 
Anti-Self-renewal 
Targeting  key  signaling  pathways  for  CSC 
self-renewal  is  one  approach  to  therapy  [123,  152, 
153]. The Wnt/-catenin signaling pathway is clearly 
important  for  the  self-renewal  and  maintenance  of 
stem  cells  [35].  Several  experimental  studies  have 
demonstrated  a  decreased  proliferation  and  an  in-
creased  apoptosis  resulting  from  inhibiting  the 
Wnt/-catenin  signaling  pathway  [154].  The 
Wnt/-catenin signaling pathway can be inhibited in 
a  number  of  ways;  for  example,  Dickkopf1  (Dkk1) 
binds to low-density LRP6 and prevents formation of 
the Fzd-Wnt-LRP6 complex [155]. A new approach to 
antagonize Wnt signaling has been the development 
of  small  molecules  (XAV939)  to  inhibit  the  enzyme 
tankyrase that normally destroys the scaffold protein 
axin, a crucial component of the -catenin destruction 
complex  [156].  Furthermore,  antibody-based  thera-
peutic  approaches  targeting  EpCAM  are  currently 
being  developed  [157,  158].  EpCAM-directed  thera-
pies  will  be  efficacious  in  eradicating  Ep-
CAM-expressing CSCs. 
The  Hedgehog  pathway  is  another  potentially 
druggable  target  for  CSC  eradication.  Several 
small-molecule  modulators  of  Sonic  hedgehog  sig-
naling have been used to regulate the activity of this 
pathway  in  medulloblastoma,  basal  cell  carcinoma, 
pancreatic cancer, prostate cancer and developmental 
disorders [159]. In liver cells, suppression of the Sonic 
Hedgehog  pathway  by  siRNA  not  only  decreased 
HCC cell proliferation but also chemosensitized the 
cells to 5-fluorouracil (5-FU) and to the induction of 
cell apoptosis [160]. Furthermore, in hepatoblastoma, 
blocking  Hh  signaling  with  the  antagonist  cyclopa-
mine had a strong inhibitory effect on cell prolifera-
tion of hepatoblastoma cell lines [161]. Thus, targeting 
intracellular pathways associated with self-renewal of 
CSCs remains a viable approach to be extended in the 
near future. 
Anti-Tumor growth and inducing tumor cell differentia-
tion 
PTEN  plays  a  role  in  the  expansion  of  the 
CD133+  liver  CSC  population  in  liver-specific 
PTEN-deleted  mice,  which  supports  PTEN  as  a 
promising target in HCC therapy [162]. In addition, 
TGF-  family  proteins  have  also  emerged  as  key 
players in promoting the growth of stem cells in their 
undifferentiated state. A recent investigation revealed 
normal  hepatic  stem  cells  committing  to  malignant 
transformation due to aberrant TGF- and activated 
IL-6 signaling [74, 163]. Therefore, inhibition of IL-6 
signaling may be a potential therapeutic strategy in 
liver cancer treatment [163, 164]. 
CSC cells, which only make up a small propor-
tion in cancer, have the capability to sustain tumor 
growth and are more resistant to conventional chem-
otherapy than  other differentiated cancer cells. One 
approach to treat malignancies is to induce differen-
tiation of the CSC cells. Differentiation therapy could 
force  hepatoma  cells  to  differentiate  and  lose  their 
self-renewal  property.  Hepatocyte  nuclear  factor-4 
(HNF4),  a  central  regulator  of  differentiated 
hepatocyte  phenotype,  suppresses  a  tumorigenesis 
and tumor development by inducing HCC differenti-
ation, especially CSC cells [165]. Interferon therapy is 
effective  for  eradicating  hepatitis  viruses  and  also 
preventing the development of HCC. Interferon alpha 
treatment accelerated hepatocytic and biliary differ-
entiation in oval cell lines [166]. Interferon could be 
applied to the treatment of HCC by targeting CSCs. In 
addition,  oncostatin  M  (OSM),  an  interleukin 
6-related cytokine known to induce differentiation of 
hepatoblasts into hepatocytes, could be used to effec-
tively  induce  differentiation  and  cell  division  of 
dormant EpCAM+ liver CSCs, and the combination of 
OSM and conventional chemotherapy with 5-FU effi-
ciently eliminates HCC by targeting both CSCs and 
non-CSCs [167]. These findings indicate that combi-
nation  of  differentiation  therapy  and  conventional 
chemotherapy may be an effective treatment of HCC. 
 Liver stem/progenitor cell markers 
The identification of CSC markers and their ex-
ploitation in targeted chemotherapy is an important 
research goal. It has been shown that CSCs in HCC 
can be identified by several cell surface antigens, e.g., 
CD133, CD90, CD44, OV6, and EpCAM, or by select-
ing the SP cells by Hoechst dye-staining. Given the 
phenotypic  similarities  between  CSCs  and  normal 
stem  cells,  it  is  reasonable  to  infer  that  the  surface 
phenotype of CSCs resembles that of normal hepatic 
stem cells.  
Anti-CD133 
CD133/prominin-1,  a  pentaspan  membrane 
glycoprotein, is an important cancer stem cell surface 
marker in various solid tumor types, including liver 
[168,  169].  CD133  expressing  cells  have  been  sug-
gested to be critical tumorigenic progenitors in HCC, 
conferring chemoresistance by preferential activation 
of  the  AKT/PKB  and  Bcl-2  cell  survival  response 
[170].  The  treatment  of  CD133+  HCC  cells  with  an 
AKT1  inhibitor,  specific  to  the  Akt/PKB  pathway, 
significantly  reduced  the  expression  of  the  survival 
proteins. In addition, suppression of CD133 by a mu-Int. J. Biol. Sci. 2011, 7 
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rine antibody to human CD133 conjugated to a potent 
cytotoxic  drug  reduced  the  proliferation  rate  of 
Hep3B cells in vitro and delayed tumor growth in a 
SCID mouse model [171]. These findings suggest that 
targeting  of  CD133  might  be  a  novel  therapeutic 
strategy for liver tumors. 
Anti-CD44 
CD133+/CD44+  HCC  cells  were  more  tumoi-
genic than those of CD133+/CD44- cells in vivo. A re-
cent study suggested that CSC phenotype could  be 
precisely  defined  by  co-expression  of  CD133  and 
CD44 cell surface markers [172]. CD133+/CD44+ HCC 
cells showed stem cell properties, including extensive 
proliferation, self-renewal and differentiation into the 
bulk of cancer cells. In addition, recent studies also 
revealed that blocking CD44 signaling using an an-
ti-CD44  antibody  might  be  a  potential  strategy  to 
eradicate liver CSCs and consequently cure those pa-
tients [172]. 
Anti-EpCAM 
Currently, several EpCAM-targeting antibodies 
are  in  clinical  development,  which  include  Ca-
tumaxomab (Fresenius Biotech) and Adecatumumab 
((MT201)  Micromet,  Inc.).  Clinical  trials  have  been 
conducted in various cancers, including breast, pros-
tate and colon cancers [157, 158]. In liver cells, RNAi 
targeting of EpCAM significantly decreased the CSC 
pool and reduced both tumorigenicity and invasive 
capacity of CSCs [37, 173]. Since EpCAM expression is 
a downstream target of Wnt/-catenin, these results 
may have implications for development of novel tar-
get therapies. 
Anti-CD13 
Recently, CD13 was identified as a marker for 
semiquiescent  CSCs  in  human  liver  cancer  cells.  In 
mouse xenograft models, combination of a CD13 in-
hibitor and 5-FU dramatically reduced tumor volume 
compared  with  either  agent  alone.  5-FU  inhibited 
proliferating CD13+ semiquiescent CSCs, while CD13 
inhibition  suppressed  the  self-renewing  and  tu-
mor-initiating ability of dormant CSCs. These results 
indicate that combining a CD13 inhibitor with a reac-
tive oxygen species (ROS) -inducing chemo/radiation 
therapy  may  improve  the  treatment  of  liver  cancer 
[174]. 
Disruption of Microenvironment 
Hypoxia has been identified as a major cause of 
hypervascularization  in  HCC,  and  in  patients  with 
HCC,  disease  free  survival  is  shorter  when  tumors 
express  high  levels  of  hypoxia-inducible  factor-1 
(HIF-1).  Hypoxia  influences  microenvironment  in 
HCC and liver CSCs [175, 176]. Induction of tumor 
hypoxia combined with chemotherapy by transcath-
eter transarterial chemoembolization has been widely 
used  in  treating  unresectable  HCC,  but  tumor  re-
sponse rate is unsatisfactory and only a subgroup of 
patients benefit from this treatment [177, 178]. HIF-1 
may be responsible for in this failure, as suggested by 
experimental  findings  obtained  in  a  rat  model  of 
primary liver cancer [179]. Therefore, hypoxia-driven 
clonal  selection  of  apoptosis-resistant  tumor  cells, 
together with hypoxia-induced MDR1 expression and 
angiogenesis, explain why hypoxic tumors are more 
resistance  to  conventional  anticancer  therapy.  This 
justifies  the  current  trials  evaluating  the  use  of  an-
ti-angiogenic therapy following HCC surgery. Several 
studies have established that tumor growth and inva-
sion in HCC are dependent on dysregulated angio-
genesis  [180-182].  There  is,  therefore,  a  strong  ra-
tionale for targeting growth factors that drive angio-
genic process as a potential therapeutic strategy for 
the treatment of HCC. VEGF is a key angiogenic fac-
tor, and several agents that target VEGF or VEGFR are 
currently in development for the treatment of HCC 
[183,  184].  These  agents  include  the  tyrosine  kinase 
inhibitors  Vatalanib  (PTK787)  [185]  and  Cediranib 
(AZD2171) [186, 187], and the monoclonal antibody 
Bevacizumab  (Avastin;  Genentech,  Inc.,  South  San 
Francisco, CA, USA) [188], and multikinase inhibitors 
Sorafenib (Nexavar; Bayer HealthCare Pharmaceuti-
cals  Inc.,  Wayne,  NJ,  USA)  [189-194],  Sunitinib 
(Sutent; Pfizer Labs, New York, NY, USA) [195, 196], 
Brivanib  (BMS-582664)  [197-199],  and  Linifanib 
(ABT-869) [199]. In addition, ligands that bind to the 
EGFR, such as EGF, have a vital role in both tumor 
angiogenesis and proliferation, thought to be primar-
ily  through  activation  of  the  RAF/MEK/ERK  and 
PI3K/AKT/mTOR  pathways.  Because  of  their  effi-
cacy  in  other  solid  tumors  and  the  integral  role  of 
growth factors in HCC development and progression, 
it was hypothesized that agents specifically targeting 
EGF/EGFR signaling may also be beneficial in HCC. 
These  agents  include  the  tyrosine  kinase  inhibitors 
Erotinib [200, 201], Lapatinib (GW572016) [202, 203] 
and Gefitinib ((ZD1839) Iressa; Astrazeneca Pharma-
ceuticals LP, Wilmington DE, USA) [204-207], and the 
monoclonal  antibody  Cetuximab  ((IMC-C255)  Er-
bitux;  ImClone  LLC,  New  York,  NY,  and  Bris-
tol-Myers Squibb, Princeton, NJ, USA) [208, 209].  
Disruption of self-protection 
Anti-immune evasion 
The observation that tumors progress in patients 
with  HCC  despite  the  presence  of  tumor-specific 
immune  responses  suggests  that  development  of Int. J. Biol. Sci. 2011, 7 
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HCC  leads  to  a  number  of  immunosuppressive 
mechanism,  which  are  important  to  be  considered 
when  designing  immunotherapy  protocols.  These 
mechanisms include production of immunosuppres-
sive  cytokines  such  as  TGF-  and  prostaglandins, 
impaired  antigen-presenting  cells,  generation  of  in-
hibitory macrophages, increase in regulatory T cells 
and  induction  of  myeloid-derived  suppressor  cells 
(MDSC).  All  these  factors  provide  an  environment 
that promotes angiogenesis, tumor survival and me-
tastasis. 
Targeting  regulatory  T  cells  has  been  of  great 
interest to potentially remove the suppression of ef-
fecter  T  cells  and  enhance  tumor-specific  immune 
response.  Depletion  of  regulatory  T  cells  using  an-
ti-CD25  monoclonal  antibodies  or  regulatory  T 
cell-inhibiting agents, such as cyclophosphamide, has 
been shown to have anti-tumor effects in preclinical 
models  [210-213].  In  addition,  MDSC  suppress  the 
cytokine production as well as the cytotoxic capacity 
of natural killer (NK) cells, playing a critical role in the 
host  defense  against  cancer,  in  HCC  patients  [214]. 
Impaired NK cells can affect anti-tumor immune re-
sponses,  which  contributes  further  to  tumor  escape 
from both innate and adaptive immune responses in 
patients with HCC. 
Anti-multiple drug resistance 
Survival  of  stem-like  cells  in  response  to 
chemotherapeutic drugs is thought to be governed by 
the presence of active transmembrane adenosine tri-
phosphate-binding cassette (ABC) transporter family 
members, such as MDR1, ABCG2 and ABCC2 [215]. It 
is believed that stem-like SP cells, which are known 
for  their  ability  to  efflux  the  DNA-binding  dye 
Hoechst 33342, confer resistance to chemotherapeutic 
drugs, including cisplatin and doxorubicin, through 
expression high levels of such ABC transporters [216, 
217]. In SP cells purified from HCC cell lines, inhibi-
tion  of  MDR1,  ABCG2  and  ABCC2  reverses  their 
chemoresistance [218]. These cells have been shown to 
harbor other CSC-like properties, and may be related 
to  the  metastatic  potential  and  chemoresistance  of 
HCC [219]. Moreover, it was demonstrated that ex-
pression  of  granulin-epithelin  precursor  (GEP)  and 
ABCB5  in  liver  CSCs  is  associated  with  chemo-
resistance and reduced survival times of patients with 
HCC [175].  
Anti-Radioresistance 
Several experimental and clinical findings pro-
vide evidence that the number of CSCs in  a cancer 
affects its radiocurability. Recurrent tumors after ra-
diotherapy could originate from one surviving CSC, 
and a permanent local tumor control requires inacti-
vation of all CSCs [220]. Tumor cell hypoxia and tu-
mor  cell  repopulation  are  the  main  factors  causing 
radioresistance. Oxygen mediates the majority of the 
biological effects of sparsely ionizing radiation, and 
the response of cells to radiation depends strongly on 
the availability of oxygen. Various methods to deliver 
oxygen to cancer tissue have been studied. Enhanced 
tumor oxygenation has previously been achieved in 
an animal model using the synthetic heme-based ox-
ygen carrier, albumin-heme which is a recombinant 
human  serum  albumin-Fe  cyclohexanoil  heme 
(rHSA-FeP).  The  rHSAFeP  is  a  candidate  radia-
tion-enhancing  drug,  and  arterial  infusion  of 
rHSA-FeP may serve as a local oxygeneation method 
that enhances the radiation effect [221]. 
Future Directions 
The rapid development of the CSC field, com-
bined  with  genome-wide  screening  techniques,  has 
allowed for the identification of important new CSC 
markers  and  pathways,  and  these  discoveries  have 
contributed  to  one  of  the  most  important  develop-
ments  in  cancer  treatment.  However,  several  im-
portant issues still remain to be resolved. Most of the 
key pathways important to CSCs are also shared by 
normal  stem/progenitor  cells  and  drugs  targeting 
these  pathways  could  have  a  detrimental  effect  on 
normal cells. For example, little is known about CSC 
directed  therapies  (e.g.  targeting  CD133  in  CD133+ 
liver CSCs). Initial results are promising, but its po-
tential  short-  and  long-term  side  effects  of  these 
therapies are unclear. Such therapies will, if not spe-
cific for CSCs, lead to tissue and/or  organ damage 
due to the depletion of the reserve/regenerative stem 
cells.  Such  treatment  with  off-target  effects  lead  to 
acute  and  irreversible  organ  failure.  Therefore,  it  is 
critical  in  delineating  the  molecular  differences  be-
tween CSCs and their tissue specific stem cell coun-
terparts, to prevent damage to normal somatic stem 
cells  and  to  ensure  selectively  targeting  CSCs.  This 
growing knowledge base has the potential to identify 
candidate genes and pathways that are important for 
CSC survival and propagation but are not important 
for normal stem cell function. 
 In addition, CSCs clearly have a complex path-
ogenesis, with the potential for considerable crosstalk 
and  redundancy  in  signaling  pathways,  and  hence 
targeting single molecules or pathways may have a 
limited benefit in treatment. Use of combinations of 
therapies  may  be  needed  to  overcome  the  complex 
network of signaling pathways, and ultimately inhibit 
the signaling that controls tumor growth and survival. 
However, use of a combination regimen can lead to Int. J. Biol. Sci. 2011, 7 
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tolerability and drug-drug interaction problems, and 
hence an alternative approach is to use molecularly 
targeted agents that have multiple modes of action. It 
is useful to understand which combination regimen is 
the  most  effective  for  inhibiting  CSC  survival  and 
propagation with the least impact on normal stem cell 
function. When a sufficient number of CSC markers 
become available and an ideal combination therapy 
identify, CSC-specific therapies might be developed 
that  spare  healthy  stem  cells  and  thus  reduce  side 
effects and retain regenerative tissue capacities. Dis-
coveries  made  in  the  CSC  field  will  feed  back  into 
other areas of stem cell research because many marker 
gene  products  found  in  CSCs  are  shares  with  the 
normal stem cell population. It is also expected that a 
better  understanding  of  the  processes  that  control 
autonomous  growth,  differentiation  and  cell  migra-
tion  will  contribute  to  novel  regenera-
tive-medicine-based  treatments  that  will  revolution-
ize therapeutic strategies and bring renewed hope to 
cancer patients. 
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